Modality
Small Molecule
MOA
CGRPant
Target
CGRP
Pathway
Wnt
CholangiocarcinomaMDDALS
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
~May 2021
→ ~Aug 2022
Phase 2
Nov 2022
→ Feb 2028
Phase 2Current
NCT06453885
1,185 pts·ALS
2022-11→2028-02·Completed
1,185 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-181.9y awayPh3 Readout· ALS
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Complet…
Catalysts
Ph3 Readout
2028-02-18 · 1.9y away
ALS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06453885 | Phase 2/3 | ALS | Completed | 1185 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| INC-2432 | Incyte | Phase 2 | CD47 |